 DURHAM, N.C., May 19, 2021 GLOBE NEWSWIRE -- Heat Biologics, Inc. Nasdaq: HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured in several presentations and panel discussions at the 3rd Annual Treg Directed Therapies Summit on May 19-20. PTX-35 is a novel, potential first-in-class antibody modulating TNFRSF25 death receptor 3 or DR3, a receptor that is preferentially expressed by antigen-experienced T-cells. 